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Decreased insulin sensitivity in patients with hypopituitarism without GH replacement
(pHP-WGHR) remains conflicting in literature. It is known that these patients present a
decrease in free fat mass and an increase in fat mass. Typically, these kinds of alterations
in body composition are associated with a decrease in insulin sensitivity; however,
there is no consensus if this association is found in pHP-WGHR. Thus, we investigated
pHP-WGHR regarding insulin sensitivity by euglycemic hyperinsulinemic clamp, the gold
standard method, and body composition. In a cross-sectional study, we evaluated 15
pHP-WGHR followed up in a Service of Neuroendocrinology and 15 individuals with
normal pituitary function as a control groupwith similar age, gender and bodymass index.
Insulin sensitivity was evaluated by euglycemic hyperinsulinemic clamp and homeostatic
model assessment insulin resistance (HOMA-IR). Kappa coefficient evaluated the
agreement between these two methods. Percentage of fat mass, percentage of free
fat mass, fat mass weight and free fat mass weight were assessed by electrical
bioimpedance. The pHP-WGHR presented similar insulin sensitivity to control group by
euglycemic hyperinsulinemic clamp, both by the M-value, (p = 0.0913) and by the area
under the glucose infusion rate curve, (p = 0.0628). These patients showed lower levels
of fasting glycemia (p = 0.0128), insulin (p = 0.0007), HOMA-IR (p = 0.009). HOMA-IR
shows poor concordance with euglycemic hyperinsulinemic clamp (Kappa = 0.16) in
pHP-WGHR, while in the control group the agreement was good (Kappa = 0.53). The
pHP-WGHR presented higher values of percentage of fat mass (p = 0.0381) and lower
values of percentage of free fat mass (p = 0.0464) and free fat mass weight (0.0421)
than the control group. This study demonstrated that the insulin sensitivity evaluated
by euglycemic hyperinsulinemic clamp in pHP-WGHR was similar to individuals with
normal pituitary function, despite the pHP-WGHR presenting higher fat mass percentage.
HOMA-IR was not a good method for assessing insulin sensitivity in pHP-WGHR.
Keywords: hypopituitarism, GH deficiency, euglycemic hyperinsulinemic clamp, insulin sensitivity, fat mass, free
fat mass
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INTRODUCTION
Hypopituitarism (HP) results from complete or partial deficiency
in pituitary hormones from several etiologies and includes
adrenal insufficiency, hypothyroidism, hypogonadism, growth
hormone deficiency (GHD) and rarely diabetes insipidus (1).
These patients need a replacement of these hormones according
to current guidelines standard (1–3).
Decreased in insulin sensitivity has been noted in patients
with hypopituitarism without GH replacement (pHP-WGHR),
an alteration attributed to the GHD (4–7). However, there are
animals and human studies suggesting that insulin sensitivity is
not decreased in GHD (7–12). It is known that these patients
present a decrease in free fat mass (FFM) and an increase in
fat mass (FM) (13–16). Classically, these kind of alterations
in body composition are associated with a decrease in insulin
sensitivity, albeit there is no consensus if this association is
found in pHP-WGHR. On the other hand, some authors have
demonstrated the opposite; increased insulin sensitivity in these
patients when compared with a control group matched for
age, sex and body mass index (BMI) (9–12). We highlight
that the authors of the mentioned studies that evaluated
insulin sensitivity used different methods of evaluation to
the homeostatic model assessment (HOMA-IR), the frequently
sampled intravenous glucose tolerance tests with minimal model
analysis or euglycemic hyperinsulinemic clamp (EHC) (4–12).
Due to these contradictory results and scarce studies with
the gold standard method to evaluate insulin sensitivity,
euglycemic hyperinsulinemic clamp, we performed a study using
this method in patients with hypopituitarism without growth
hormone replacement compared to a control group composed
by individuals with normal pituitary function paired by BMI,
gender, and age and additionally, we evaluated the characteristics
of body composition in these groups.
MATERIALS AND METHODS
Study Design
This was a cross-sectional study. We evaluated patients with
a previous diagnosis of HP; all followed in the Service of
Neuroendocrinology of the hospital of the University of
Campinas between the years 2016 and 2018. All patients were
on levothyroxine, prednisone, estrogen and progesterone
or testosterone replacement and none on GH therapy. We
TABLE 1 | Frequency of pituitary hormone deficiencies and replacement therapy
in patients with HP and control subjects.




GH deficiency/treatment 15/0 0/0
ACTH deficiency/treatment 15/15 0/0
TSH deficiency/treatment 15/15 0/0
LH-FSH deficiency/treatment 15/14 0/0
ADH deficiency/treatment 4/4 0/0
HP, Hypopituitarism.
evaluated the age, gender and BMI clinically, etiology of HP,
basal metabolic rate (BMR), BC variables such as percentage
of fat mass (PFM), percentage of free fat mass (PFFM), fat
mass weight (FMW), and free fat mass weight (FFMW) by
means of electrical bioimpedance. Besides that, we evaluated
fasting glucose and insulin used for calculated HOMA-IR and
insulin sensitivity by Euglycemic hyperinsulinemic clamp.
The associations between body composition characteristics
and insulin sensitivity of HP patients were compared
with the control subjects. The control group consisted of
individuals with normal pituitary function, paired by age,
gender and BMI. All patients and control subjects included
in this study were of Caucasoid etnia. The local Ethics
Committee approved the study (CAAAE 1.531.415) and all
participants written and signed an informed consent form.
Patients
Fifteen patients with HP were included without residual tumor
or previous functioning tumor between 20 and 59 years old.
Data regarding age, sex, height, and weight measures were
assessed. The diagnosis of HP was made in the presence of
deficiency of thyroid-stimulating hormone (TSH), free T4 (FT4),
adrenocorticotropic hormone (ACTH), basal cortisol, growth
hormone (GH), insulin-like growth factor (IGF-1), luteinizing
hormone (LH), follicle stimulating hormone (FSH), total and
free testosterone (in male patients) or estradiol (in women).
An insulin tolerance test was performed for the diagnosis
of GH and cortisol deficiency. All patients were replaced
with levothyroxine (mean dose 1.56 mcg/kg/day), prednisone
(mean dose 2.2 mg/m²/day) and estrogen/progesterone (17β
estradiol 2mg+ norethisterone acetate 1mg/day) or testosterone
(testosterone cypionate 200mg every 3 weeks), dosages were
monitored and adjusted as required according to current
guideline standard. Adequate replacement was assumed when
medication had not been adjusted for at least 6 months, patients
had no complaints, and basal hormone levels were within the
recommended values. Patients participating in the study do not
present contraindications for GH replacement.
Exclusion criteria were residual pituitary tumor or previous
functioning tumor, glucose intolerance, diabetes mellitus,
acutely infirm patients, malignant tumors, active inflammatory
disease, class III/IV heart failure (NYHA classification), severe
hepatic disease (low albumin or increased IRN), advanced kidney
disease (stage 4 or 5), HIV or psychiatric diseases.
Control Group
Fifteen individuals without pituitary disease with normal
pituitary function defined by previous hormonal evaluation,
paired by age, gender and BMI, were recruited as a control
group in the same period and following the same criteria for
exclusion applied to patients with HP. The individuals were
recruited among the relatives of patients from the outpatient
neuroendocrinology clinic. The same clinical, insulin sensitivity
and body composition characteristics evaluated in the group of
patients with HP were assessed in the control group.
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Clinical and Body Composition Parameters
Clinical data were recorded consisting of age, sex, BMI, and
etiology of HP. BMI was calculated based on the ratio between
body mass (in kg) and squared height (in meters). In all the
study subjects, BMR and BC variables were evaluated by electrical
bioimpedance with a Biodynamics monitor (Biodynamics Corp.,
Seattle, WA, USA) as described by Boulier et al. (17). The
measurements were taken in the morning after each subject
had fasted at least 10 h and bladder voided. The subject had
been supine for at least 5min, arms relaxed at the sides but not
touching the body and thighs separated.
Laboratory Measurements
Insulin was measured by Human Insulin Elisa Technique
(Millipore, Billerica, Massachusetts, USA), RV: 2.0–200 µU/ml
(CV= 4.64%) and plasma glucose was measured with the glucose
oxidase method using an YSI glucose analyzer (YSI 2300-Stat
Plus analyzer; YSI, Yellow Springs, OH, USA; RV: 70–100 mg/dl).
HOMA-IR was calculated by the formula insulin × glucose/22.5
(18, 19). Individuals who presented HOMA-IR > 2.7) were
considered insulin resistant (20).
Clamp Study
The Euglycemic hyperinsulinemic clamp study, which was
carried out after an overnight (12 to 14 h) fast, consisted of
2 h of euglycemic insulin infusion at a rate of 40 µU/min per
meter squared of body surface area and was preceded by a 2-
h control period as previously described (21). A polyethylene,
20-gauge catheter was inserted into an antecubital vein for the
infusion of insulin and glucose. Another catheter was inserted
retrograde into a wrist vein, and the hand was placed in a heated
box (50–60◦C) for the sampling of arterialized blood. Following
this procedure, the patients rested for at least 30min in the
supine position. The infusion was adjusted according to glucose
determinations made every 5min on a glucose analyzer (Yellow
Springs Instruments, Yellow Springs, OH). The venous samples
for insulin measurements were obtained at 30min intervals
during the 2 h of the clamp. For calculation of insulin sensitivity
from the Glucose Infusion Rate (GIR) curve and the glucose
disposal rate (M-value) (milligrams per kilogram per minute)
were calculated from the infusion rate of exogenous glucose
during the second hour of the insulin clamp period, M-value and
GIR were normalized per kg FFM and per kg FFM/Glycemia,
this last normalization was multiplied by 100 (21, 22). At the
end, subjects who presented M <4.8mg (corrected by MM) were
considered insulin resistant (23).
Statistical Analysis
To describe the profile of the sample according to the variables
under study, the frequency tables of the categorical variables with
absolute (n) and percentage (%) values were used. Descriptive
statistics of the numerical variables, with values of mean,
standard deviation, minimum values and maximum and median
were performed. Categorical variables were compared using
the Chi-square test and, when necessary, Fisher exact test.
Mann-Whitney test was used to compare numerical variables.
To evaluate the agreement between the measurement M-value
(corrected by FFM) and the HOMA-IR, the Kappa test was used
(24). Confidence interval (CI) was 95%. The level of significance
adopted for the study was 5%.
RESULTS
Clinical Characteristics of Hypopituitary
Patients
The etiology of HP included congenital pituitary hypoplasia
(6 patients), non-functioning macroadenomas (postsurgical-3











PFFM (%) PFM (%)
Pt-1 F 32 22.06 P-L-Es/Pg 22.67 0,3 6 8.51 65.4 34.6
Pt-2 M 50 31.92 P-L-T 18.8 3.1 4.94 5.90 65.7 34.3
Pt-3 F 56 41.21 P-L 47.64 1.6 2.81 2.96 56.6 43.4
Pt-4 M 50 17.78 P-L-T 31 0.4 6.83 9.36 76.2 23.8
Pt-5 M 41 31.50 P-L-T-D 30.11 1.7 2.87 3.11 63.5 36.5
Pt-6 F 42 46.00 P-L-Es/Pg 31.5 0.4 4.45 5.83 66.3 33.7
Pt-7 M 40 18.80 P-L-T 34.44 0.3 10.52 15.02 75.9 24.1
Pt-8 M 32 24.61 P-L-T-De 52.6 0.4 8.78 11.61 77.5 22.5
Pt-9 M 23 21.90 P-L-T 40.1 0.4 10.63 13.57 62.2 37.8
Pt-10 M 24 17.70 P-L-T-D 18.39 0.4 13.7 19.96 65.4 34.6
Pt-11 M 25 20.28 P-L-T 36.33 0.4 12.93 16.82 79.6 20.4
Pt-12 M 22 35.08 P-L-T-D 69.65 3.3 3.02 3.58 68.5 31.5
Pt-13 F 24 21.52 P-L-Es/Pg 25.4 0.4 12.53 16.36 70.3 29.7
Pt-14 F 22 23.14 P-L-Es/Pg 36.69 0.3 4.84 6.5 70.1 29.9
Pt-15 F 22 19.80 P-L-Es/Pg 71.68 0.4 7.84 8.82 67.8 32.2
pHP-WGHR, patients with hypopituitarismwithout GH replacement; Pt, patient; P, prednisone; L, levothyroxine; Es/Pg, Estrogen/Progesterone; D, Desmopressin; HOMA-IR, homeostatic
model assessment of insulin resistance; M/FFM, M-value normalized per kg Free Fat Mass; M/FFM/Gly, M-value normalized per kg Free Fat Mass and Glycemia; PFM, Percentage of
Fat Mass; PFFM, Percentage of Free Fat Mass.
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patients), craniopharyngioma (postsurgical-3 patients), empty
sella (2 patients) and Sheehan’s Syndrome (1 patient). The
deficiencies of pituitary hormones and treatment of HP patients
compared to control group are presented in Table 1. The
individual description of each patient in the study group
regarding treatment, levels of IGF-1, insulin sensitivity and body
composition are shown in Table 2.
Our study included 15 patients with hypopituitarism (6
females) and a control group of 15 individuals (6 females). The
two groups did not present significant differences in age, gender
and BMI. On the other hand, levels of IGF-1 were significantly
lower in patients with HP: Table 3.
Insulin Sensitivity and Glucose Metabolism
in pHP-WGHR
Regarding insulin sensitivity, we found that M-value and
area under the GIR curve were not statistically different
between patients and control group as shown in Table 3,
TABLE 3 | Comparative analysis of clinical characteristics, body composition and
insulin sensitivity between patients with HP and control subjects.





Sex (female) 6 (40%) 6 (40%) 1.000
Age (years) Mean ± SD 33.7 ± 11.9 34.0 ± 11.4 0.8679
Median (min-max) 32.0 (22.0-56.0) 30.0 (21.0–54.0)
BMI (kg/m²) Mean ± SD 26.2 ± 8.9 27.8 ± 8.8 0.2808
Median (min-max) 22.1 (17.7–46.0) 23.6 (17.9–48.6)
IGF-1(ng/ml) Mean ± SD 38.1 ± 16.1 170.9 ± 67.9 <.0001
Median (min-max) 34.4 (18.4–71.7) 157.2
(75.4–286.1)
F-Gly (mg/dl) Mean ± SD 78.3 ± 7.6 86.0 ± 7.8 0.0128
Median (min-max) 77.5 (69.7–92.5) 87.2 (73.2–97.4)
F-Insul (µU/ml) Mean ± SD 3.4 ± 3.7 8.5 ± 7.6 0.0007
Median (min-max) 2.0 (0.9–14.9) 4.9 (2.1–28.0)
HOMA-IR Mean ± SD 0.9 ± 1.0 1.8 ± 1.7 0.0090
Median (min-max) 0.4 (0.3–3.3) 0.9 (0.4–6.2)
M/FFM (mg/kg/min) Mean
± SD
7.5 ± 3.8 5.5 ± 2.1 0.0913
Median (min-max) 6.8 (2.8–13.7) 5.7 (2.4–9.5)
M/FFM/Gly (mg/kg/min)
Mean ± SD
9.9 ± 5.4 6.4 ± 2.7 0.0890
Median (min-max) 8.8 ± (2.9–19.9) 6.1 (2.5–11.2)
PFFM (%) Mean ± SD 68.7 ± 6.3 75.0 ± 9.8 0.0464
Median (min-max) 67.8 (56.6–79.6) 75.3 (55.6–92.9)
PFM (%) Mean ± SD 31.3 ± 6.3 25.0 ± 10.2 0.0381
Median (min-max) 32.2 (20.4–43.4) 4.7 (7.1–44.4)





Values are shown as mean (standard deviation), Median (min-max) or number and
frequency (percentage).
HP, Hypopituitarism; BMI, body mass index; F-insulin, Fasting insulin; F-Glycemia, Fasting
Glycemia; HOMA-IR, homeostatic model assessment of insulin resistance; M/FFM, M-
value normalized per kg Free Fat Mass; M/FFM/Gly, M-value normalized per kg Free Fat
Mass and Glycemia; PFM, Percentage of Fat Mass; PFFM, Percentage of Free Fat Mass;
BMR, Basal Metabolic Rate.
Figures 1, 2 respectively. Patients with hypopituitarism without
GH replacement showed significant lower levels of fasting
glycemia, insulin and HOMA-IR (Table 3). We found that the
glycemia curve values during the clamp were significantly lower
in the group of pHP-WGHR compared with control subjects
(Figure 3). There were no differences between the insulin levels
in pHP-WGHR patients and control subjects (Figure 4). In the
assessment of SI, the agreement of the HOMA-IR with the EHC
method in the pHP-WGHR was weak (Kappa = 0.16; CI95%
= 0.000–0.734) and in control subjects was moderate (Kappa =
0.53; CI95%= 0.062–0.990).
Body Composition of Patients With
HP-WGHR
Patients with HP-WGHR had higher percentage of fat mass
and lower percentage of free fat mass and basal metabolic rate,
compared with control subjects (Table 3).
DISCUSSION
Our study demonstrated that, using the EHC method, pHP-
WGHR presented similar insulin sensitivity when compared to
the control group as lower levels of fasting glycemia, fasting
insulin and HOMA-IR. Additionally, we verified that HOMA-
IR had a poor concordance with the EHC method for assessing
insulin sensitivity in pHP-WGHR. At the same time, we observed
that pHP-WGHR had higher fat mass and lower amount of free
fat mass.
Our findings are not in agreement to some similar studies
in the literature that showed decreased insulin sensitivity
in pHP-WGHR (5, 6). Besides the difference between the
studied populations, this difference could be explained
by the management of hypopituitarism, because currently
the recommended hormone replacement doses are more
physiological than those used previously (1).
We also found differences in other markers associated to
insulin sensitivity, such as lower levels of fasting glycemia, insulin
and HOMA-IR, in accordance with other authors and suggesting
that pHP-WGHR do not have decreased insulin sensitivity
(8–12, 25–29).
Interestingly, the presence of lower blood glucose levels in
the patients during the clamp, despite similar insulin levels
when compared to the control group, may be a consequence of
a greater sensitivity of peripheral tissues to exogenous insulin
(30). Another explanation would be the decrease of glycogen
stores in muscle and liver, as already demonstrated in animal
studies with GH receptor knockout (31, 32). This finding
could explain why patients with hypopituitarism have a higher
hypoglycemic response to insulin and take longer to recover from
hypoglycemia (30).
The deficiency of GH (insulin counter-regulatory hormone)
and decrease of the glucose hepatic production rate, may
explain the lower glucose levels in these patients (30, 33, 34).
Furthermore, the decrease of serum IGF-1 in these patients
would lead to an increased expression of the IGF-1 receptor.
The binding of insulin to IGF-1 receptors could justify the lower
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FIGURE 1 | Glucose Infusion Rate (GIR) corrected for the Free Fat Mass (FFM) in patients with hypopituitarism and control subjects during the Euglycemic
Hyperinsulinemic Clamp (mean values every 10min) p = 0.16. AUC, Area Under the Curve. For the calculation of the areas under the curve (AUC) only the average
values of the last hour were used.
FIGURE 2 | Glucose Infusion Rate (GIR) corrected for the Free Fat Mass (FFM) and Glycemia (GLY) in patients with hypopituitarism and control subjects during the
Euglycemic Hyperinsulinemic Clamp (mean values every 10min) p = 0.12. AUC, Area Under the Curve. For the calculation of the areas under the curve (AUC) only the
average values of the last hour were used.
FIGURE 3 | Serum glycemia in patients with hypopituitarism and control subjects during the Euglycemic Hyperinsulinemic Clamp (mean values from time 0, every
10min) p = 0.009. AUC, Area Under the Curve. For the calculation of the areas under the curve (AUC) mean values of glycemia during the clamp were used.
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FIGURE 4 | Serum insulin level in patients with hypopituitarism and control subjects during the Euglycemic Hyperinsulinemic Clamp (mean: 0, 30, 60, 90, and
120min) p = 0.7089. AUC, Area Under the Curve. For the calculation of the areas under the curve (AUC) mean values of insulin during the clamp were used.
blood insulin levels found in our patients. Additionally, the
action of insulin via the IGF-1 receptor could decrease glucose
levels, as previously demonstrated in animal models (35), which
could result in lower values of HOMA-IR in these patients.
It is important to highlight that these patients presented
an increased insulin sensitivity by the HOMA-IR method, but
not by the clamp, the gold standard method. This difference
could be explained by the different concepts of two methods.
Thus, HOMA-IR evaluate insulin sensitivity in the fasting state,
since patients with GHD presents a decrease in the rate of liver
glucose production, fundamentally in fasting, which would lead
to lower levels of glycemia and insulin, resulting in lowerHOMA-
IR values (30, 33). On the other hand, the hyperinsulinemic
euglycemic clamp is based on the concept that under constant
glycemic and hyperinsulinemic conditions, with suppression
of liver glucose production, the amount of glucose consumed
by the tissues should be equivalent to the amount of glucose
infused during the test (36). This suppression of the hepatic
glucose production would exclude a possible interference derived
from GHD. So, it is possible to explain why the concordance
index between HOMA-IR and clamp was poor in pHP-WGHR,
suggesting that HOMA-IR could not be a good method for
assessing insulin sensitivity in these patients, because this method
is not able to define the influence of the liver or peripheral
tissues on insulin sensitivity and does not take into account
the decrease in the hepatic production of glucose presented in
pPH-WGHR (36).
Patients with secondary adrenal insufficiency may frequently
have residual cortisol secretion and need the optimization of
the doses of glucocorticoids to avoid the consequences of
excessive doses (37). Because of this, we performed the tailoring
of glucocorticoids replacement in our patients. Few studies
have evaluated whether glucocorticoid dosing and regimen
change insulin sensitivity. In relation to the doses, a recent
study has shown that doses ≤20 mg/day of hydrocortisone,
which corresponds to 25mg of cortisone acetate or 5mg
of prednisolone, does not alter insulin sensitivity when
compared to 30 mg/day of hydrocortisone (38). Regarding
the therapeutic regimen, a study performed with euglycemic
hyperinsulinemic clamp showed that insulin sensitivity does not
change when compared to traditional oral replacement with
the continuous hydrocortisone infusion scheme mimicking the
circadian rhythm (39).
As expected, our patients showed higher values of PFM and
lower values of PFFM and BMR, in agreement with other studies,
pointing to the classic characteristics of pHP-WGHR (13–16, 40–
49), even with normal BMI (15). These findings could be the
consequence of the anabolic effect of GH on muscle and lipolytic
effect on adipose tissue (50).
It is known that increased percentage of fat mass in healthy
individuals is directly related to decreased insulin sensitivity.
Interestingly, the clampmethod showed that, despite unfavorable
body composition, pHP-WGHR did not present a decrease
in insulin sensitivity when compared to healthy individuals
with similar BMI, as has already been demonstrated in some
experimental studies on mice (40–42). Similar results were also
shown in the studies of a population of Ecuador patients with
GH insensitivity due to a mutant GH receptor (Laron Syndrome)
and in the cohort of patients from Itabaianinha (Brazil) who
presented GHD due to a mutation of the GH releasing hormone
receptor. We emphasize that in both populations, the HOMA-IR
and quantitative insulin check index methods were used for the
evaluation of insulin sensitivity (12, 13, 43, 44). One hypothesis
to justify this finding is it may be due to a greater increase in
subcutaneous than to visceral fat, as already demonstrated in
mice with GH receptor knockout (40). The increased visceral
fat is associated with decreased insulin sensitivity as opposed to
subcutaneous fat (51, 52). However, it is important to emphasize
that this method of electrical bioimpedanciometry could not
distinguish these fat distributions.
Clinically, patients with increased fat mass have worsened
insulin sensitivity, however we have shown that our pHP-WGHR
do not present decreased insulin sensitivity despite unfavorable
body composition. We also point out that additional studies
are needed in pHP-WGHR with GH replacement therapy to
understand the effects of GH on these parameters.
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A limitation of this study was the relatively small sample size,
due to the inclusion of patients with complete hypopituitarism,
with no residual tumor, no previous functioning pituitary tumor
and due to complex methodology of clamp study. Other studies
using EHC had similar number of patients. Another limitation
was the use of electrical bioimpedanciometry as a method
for the evaluation of body composition. However, electric
bioimpedanciometry has a good correlation with DEXA (53), the
gold standard method for the body composition evaluation.
The main strength of our study was the use of the gold
standard method in the evaluation of insulin sensitivity, the
inclusion of patients with complete pituitary hormone deficiency
and the presence of a similar control group in age, gender and
BMI, since these characteristics exert great influence on the
hormonal and metabolic variables studied (54).
CONCLUSION
Our study verified that insulin sensitivity evaluated by
euglycemic hyperinsulinemic clamp in pHP-WGHR had
similar results in control subjects with normal pituitary function
paired by age, gender and BMI, suggesting that the worsening
of insulin sensitivity was not a characteristic of these patients,
despite higher fat mass and lower free fat mass. HOMA-IR
was not a good marker for assessing insulin sensitivity in
pHP-WGHR. However, we believe that more studies are needed
to better understand the effect of GH on insulin sensitivity and
on the distribution of body fat.
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